Enzalutamide/Leuprolide Regimen Reduces Risk of Death in Prostate Cancer

Enzalutamide (Xtandi) plus leuprolide acetate exhibited a 40.3% lower risk of death compared with leuprolide acetate alone in patients with high-risk, biochemically recurrent prostate cancer, according to findings from the final overall analysis…